Oncology

CDK6

CHEMBL2508

ACCUMULATING

9,186 compounds passed ADMET with pareto_rank1 = 474. Paired with /pipeline/cdk4 selectivity arm.

ADMET Passed

9,186

Pareto Rank-1 Count

474

CRO

Awaiting CRO decision

Stage

Accumulating

Pareto Rank-1 is a front-membership count, not a quality ranking — the front is near-saturated, so it does not discriminate quality. Meaningful selection uses consensus + wet-lab.

Mechanism

CDK6 inhibition with improved hematotoxicity profile vs pan-CDK4/6.

Precedent

Same approved set as CDK4 (Palbociclib / Ribociclib / Abemaciclib).

Indications

HR+/HER2- breast cancer · NSCLC

Milestones

2026-W12

9,186 CDK6 candidates passed ADMET

2026-W15

Pareto Rank-1 frontier crystallized (474)

2026-W16

Combined CDK4/CDK6 selectivity package for CRO submission

Dashboard →Browse compounds →Methodology →